ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$61.68 USD
+1.16 (1.92%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $61.69 +0.01 (0.02%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
Brokerage Reports
0 items in cart
ANI Pharmaceuticals, Inc. [ANIP]
Reports for Purchase
Showing records 1 - 20 ( 90 total )
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Immediately Accretive Alimera Acquisition Bolsters Branded Growth Business; Raise to $94
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q24: Execution Quarter After Quarter Makes ANI Easy to Own; Raise PT to $87
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Cortrophin Gel Strength Drive 2024 Guidance Upside; Under- Levered, Looking to Build Out Rare Disease Biz; Raise to $83
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ANIP 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Gx and Established Brand Normalization Not Shocking; Cortrophin Is the Value Driver Here; Reiterate $73 Target and Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Raising Target to $73 With Outperformance Across the Business
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Very Large 1Q Beat; Raised Guidance Now Looks Conservative; Raise PT to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2023 Guidance Ahead of Us, and Likely Conservative Based on Recent Track Record; Raise PT to $53; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Moderating 2023 Estimates Ahead of Likely Conservative Guidance; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q22: Solid Execution Across Entire Business; Cortrophin Gel Rx Growth Portends 4Q Acceleration; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Story Gelling Around Cortrophin Gel Growth Inflection; Initiate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage due to reallocate our research resources.
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q17 Recap - Strong Trends and Pipeline Strength
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q17 Recap - Strong Results in a Difficult Environment
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q17 Recap - Maintained Guidance, Progress on Corticotropin
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.